AbCellera Biologics Inc. ABCL Deferred tax expense (recovery)
Deferred tax expense (recovery) at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept abcl:DeferredAndOtherIncomeTaxExpenseBenefit.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s deferred tax expense (recovery).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s deferred tax expense (recovery)?
- AbCellera Biologics Inc. (ABCL) reported deferred tax expense (recovery) of -$234.5K in Q4 2025.
- How has AbCellera Biologics Inc.'s deferred tax expense (recovery) changed year-over-year?
- AbCellera Biologics Inc.'s deferred tax expense (recovery) increased by 95.3% year-over-year, from -$4.94M to -$234.5K.
- What is the long-term trend for AbCellera Biologics Inc.'s deferred tax expense (recovery)?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s deferred tax expense (recovery) has grown at a -30.8% compound annual growth rate (CAGR), from $1.96M to -$938K.
- What does deferred tax expense (recovery) mean?
- Captures the net impact of deferred tax adjustments and other non-current tax-related items on the income statement. This metric is used to reconcile the difference between the statutory tax rate and the actual tax provision reported by the company.